Matyas Ecsedi

ORCID: 0000-0003-1341-8070
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • SARS-CoV-2 and COVID-19 Research
  • T-cell and B-cell Immunology
  • Platelet Disorders and Treatments
  • MicroRNA in disease regulation
  • Herpesvirus Infections and Treatments
  • Acute Myeloid Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • Circular RNAs in diseases
  • vaccines and immunoinformatics approaches
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Genetics, Aging, and Longevity in Model Organisms
  • Animal Virus Infections Studies
  • Multiple Myeloma Research and Treatments
  • Blood groups and transfusion
  • Viral Infectious Diseases and Gene Expression in Insects
  • Cytomegalovirus and herpesvirus research
  • Nanowire Synthesis and Applications
  • COVID-19 Clinical Research Studies
  • Rheumatoid Arthritis Research and Therapies
  • Reproductive Biology and Fertility
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • RNA Research and Splicing

Fred Hutch Cancer Center
2020-2024

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2023

Takeda (United States)
2021-2022

Cancer Research Center
2022

University Hospital of Basel
2015-2019

University of Basel
2013-2015

Friedrich Miescher Institute
2013-2015

10.1016/j.devcel.2014.12.018 article EN publisher-specific-oa Developmental Cell 2015-02-01

The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory cells, we studied biopsies and HSV-2–reactive CD4+ cells from PBMCs by cell receptor (TCR) β chain (TRB) sequencing before after vaccination with a replication-incompetent whole-virus candidate (HSV529). representation TRB sequences in repertoire increased first dose. We found sustained expansion unique, clonotypes that were not...

10.1172/jci.insight.179010 article EN cc-by JCI Insight 2024-06-18

Objectives: To explore long-term effects of treatment and prognostic relevance variables assessed at baseline during the European secondary progressive multiple sclerosis (SPMS) trial interferon beta 1b (IFNB-1b). Methods: We 362 patients (60% female; median age 41 years; Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to IFNB-1b) for their EDSS history after 10 years. Non-parametric analysis covariance (ANCOVA) multivariate linear regression models were applied. Results: Median...

10.1177/1352458515594440 article EN Multiple Sclerosis Journal 2015-09-11

Almost three years into the SARS-CoV-2 pandemic, hybrid immunity is highly prevalent worldwide and more protective than vaccination or prior infection alone. Given emerging resistance of variant strains to neutralizing antibodies (nAb), it likely that T cells contribute this protection. To understand how sequential mRNA-vectored spike (S) vaccines affect cell clonotype-level expansion kinetics, we identified cross-referenced TCR sequences from thousands S-reactive single against deeply...

10.21203/rs.3.rs-2146712/v1 preprint EN cc-by Research Square (Research Square) 2022-10-10

ABSTRACT The skin at the site of HSV-2 reactivation is enriched for HSV-2-specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory cells, we studied biopsies and HSV-2-reactive CD4 + cells from peripheral blood mononuclear (PBMCs) by cell receptor β ( TRB ) sequencing before after vaccination with a replication-incompetent whole virus candidate (HSV529). representation sequences PBMCs in repertoire increased first dose. We found sustained expansion...

10.1101/2022.02.04.22270210 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2022-02-06

<h3>Background</h3> Conditionally activated bispecific T cell engagers (TCEs) have the potential to provide a larger therapeutic window by reducing off-site on-target toxicity. Bispecific Redirected Activation (COBRAs) are novel TCEs designed be preferentially in tumor microenvironment (TME).<sup>1,2</sup> The conditionality of COBRA prodrug is mediated upon binding high affinity target domain antigen and cleavage matrix metalloproteases such as MMP9/2. results release inactive CD3e VH/VL...

10.1136/jitc-2022-sitc2022.1301 article EN Regular and Young Investigator Award Abstracts 2022-11-01

<h3>Background</h3> T Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis screening individual based tetramer binding peptide specificity, which is costly labor intensive. We developed validated a pooled approach relying...

10.1136/jitc-2021-sitc2021.192 article EN Regular and Young Investigator Award Abstracts 2021-11-01
Coming Soon ...